Last reviewed · How we verify
NCT04906031
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
Phase 2 trial testing Sodium stibogluconate in Myelodysplastic Syndromes in 5 participants. Status unknown.
1 February 2023
Quick facts
| Lead sponsor | First Affiliated Hospital of Jinan University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 1 June 2020 |
| Primary completion | 1 February 2023 |
| Estimated completion | 1 February 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sodium stibogluconate — full drug profile →
Conditions studied
- Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
- Myeloid Malignancy — all drugs for Myeloid Malignancy →
- Temperature-Sensitive p53 Mutation — all drugs for Temperature-Sensitive p53 Mutation →
Sponsor
First Affiliated Hospital of Jinan University
Who can join
Adults 18 to 75, any sex, with Myelodysplastic Syndromes or Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with p53 mutation from a defined list. The list includes 65 p53 mutations that were experimentally confirmed to be pharmacologically restored with tumor-suppressive function by antimonials.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting p53 pathways: mechanisms, structures, and advances in therapy.
Wang H, Guo M, Wei H, Chen Y. · · 2023 · cited 580× · PMID 36859359 · DOI 10.1038/s41392-023-01347-1 -
Drugging p53 in cancer: one protein, many targets.
Hassin O, Oren M. · · 2023 · cited 496× · PMID 36216888 · DOI 10.1038/s41573-022-00571-8 -
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.
Song B, Yang P, Zhang S. · · 2024 · cited 57× · PMID 38311377 · DOI 10.1002/cac2.12520 -
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy.
Czajka-Francuz P, Prendes MJ, Mankan A, Quintana Á, et al · · 2023 · cited 46× · PMID 37427115 · DOI 10.3389/fonc.2023.1200646 -
TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).
Tornesello ML. · · 2025 · cited 40× · PMID 39450536 · DOI 10.3892/ijmm.2024.5448 -
Small-molecule correctors and stabilizers to target p53.
Fallatah MMJ, Law FV, Chow WA, Kaiser P. · · 2023 · cited 30× · PMID 36964053 · DOI 10.1016/j.tips.2023.02.007 -
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53.
Mehta AK, Konopleva M. · · 2024 · cited 2× · PMID 39644032 · DOI 10.1182/hematology.2024000557 -
Unraveling the role of <i>TP53</i> mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation.
da Silva-Benedito S, Bernardo PS, Martin JE, Marty C, et al · · 2026 · PMID 41939253 · DOI 10.1002/hem3.70332
Verify or expand the search:
- PubMed search for NCT04906031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sodium stibogluconate
Trials testing the same drug.
- NCT03129646 — Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa · Phase 3 · completed
Other recruiting trials for Myelodysplastic Syndromes
Currently open trials in the same condition.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
- NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
- NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
Other First Affiliated Hospital of Jinan University trials
Trials by the same sponsor.
- NCT06752954 — The Effectiveness of Covered Stent Viabahn and Drug-coated Balloon for Complex Femoropopliteal Artery Lesions · not yet recruiting
- NCT05888558 — Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia Gravis · unknown
- NCT06286384 — Evaluating the Long-term Effects of Microfocused Ultrasound on Facial Tightening Using Quantitative Instruments · completed
- NCT06099938 — Effect of Different Labour Analgesics on Maternal and Fetal Blood Flow Observed by Doppler Ultrasonography · completed
- NCT03807986 — The Combination Therapy of Nanofat Grafting and PRP Compared With Microfat Grafting and PRP Synergy in Treating Striae D · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04906031 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Jinan University
- Last refreshed: 9 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04906031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing